about
Pathogenesis of human immunodeficiency virus infectionThe development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicHIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsStructure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structuresInhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidineIdentification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitorsA synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibitionIn vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinationsPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventTargeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studiesInhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analoguesPyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activityChimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitorsHuman immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue cultureSynergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitroLipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitroSynergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitroMechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTPA platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cellsSpecific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorspol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoAnti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strainsSynergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytesAmphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusionUnblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanismStructure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptaseHomologues of isomeric dideoxynucleosides as potential antiviral agents: synthesis of isodideoxynucleosides with a furanethanol sugar moietyGeneration and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitorThree inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replicationComparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cellsThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsThe y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stabilityPhosphorylation of nucleoside analog antiretrovirals: a review for clinicians.Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors.An Escherichia coli system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs.Solvatochromic Effects on the Absorption Spectrum of 2-ThiocytosinePenetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral actionPharmacokinetics of antiviral polyoxometalates in rats.The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C)
P2860
Q24634681-C11BE622-6944-40D8-BC58-81A6EE844118Q24655011-37A080B9-5588-4722-8D2F-61E116361170Q27670634-FA95FD16-B2F3-40F5-96C1-2DE4173D62FFQ27729365-421CC081-EB56-4C1F-A2D3-6F939A604BACQ27732012-3181D7E7-0307-40B0-9952-10298142C7B2Q28316278-DF380C51-D319-40F3-ABE4-7ACAC513AB41Q28316336-2BA7C7E1-A351-404C-94FD-17BD6C3B89E6Q28317348-3CC53960-2016-4F86-BB32-CC36E6F19F11Q28318476-0A77864A-4808-4D02-90F1-8DB738056260Q28320362-19122120-23E7-4C3A-B0DF-F801297077FFQ28320896-5A1A6838-5615-4953-BE9D-08474F495900Q28321734-CAAB7BA7-14C1-4CE2-B483-FE72EBE196A6Q28323976-528B3B22-A610-4FCF-B2F2-42DFE7BCD429Q28324145-A87CF351-6280-4AED-87D5-252BC8B5E83DQ28324214-10BE55F0-56BB-4D85-B155-F10034217C42Q28326720-FD1DA210-BE87-47BE-947E-1CCFD9B289A9Q28332188-A63FC3FE-C79F-42E5-BF77-16E17625ADC5Q28333682-DD140652-3E80-4D7A-9EB3-FEA6EDE7DC70Q28343830-258F3964-C9EC-4070-A37C-4F046DF6C6E4Q28368010-FB54B937-DF9E-4171-9236-DF243AC444BCQ28368032-FE54C22F-F73A-47A3-8EE4-524CB14AFE4AQ28368048-71F7B056-DE70-4ECC-B09F-8E17F042EB9BQ28368280-1C8B750D-242D-4938-BB0B-AC9EB835CC5CQ28369082-689D082C-6A21-447D-BF2A-AE731544477DQ28369127-54A40C66-9507-4673-9537-FB23BBA6AEB4Q28369244-DAF7188A-C3F8-4639-8A98-DFBF67D537D5Q28369309-0AB6976C-D8C9-4601-B904-842BA5C1AE94Q28375823-67151CB2-E2C8-463C-88B2-AF2373043620Q28378387-9DB46E40-6C51-4E62-85DE-5DB9FD12CF30Q28378673-E1212BED-0086-4AFE-8F09-6596E60804FCQ28378786-E0F69B54-5037-4519-BDBA-242E0A0F211CQ28379139-A992909D-F73E-46E6-B0FF-714EC6F5B0CBQ28475710-C31F21F0-A063-42DE-8912-14183E68C2E6Q31975873-311016FA-3EBC-4F89-A07B-109568F4007AQ33209407-5B4CBEBF-8B31-4A1A-9821-CCB7EF54C0D7Q33699299-2E852161-247F-4E33-B12B-2F80585D9FBCQ33735443-55126DD1-48BD-46F7-B12A-6DE454FC7246Q33745137-8F74D035-F6BC-4DA7-8F12-21BFBEEED498Q33750885-E85DC161-67E9-4EA3-A958-6CD06C6A3CA9Q33779523-4C76493C-7C3B-4C4F-8498-5488B6F44569
P2860
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Molecular targets for AIDS therapy
@ast
Molecular targets for AIDS therapy
@en
Molecular targets for AIDS therapy
@nl
type
label
Molecular targets for AIDS therapy
@ast
Molecular targets for AIDS therapy
@en
Molecular targets for AIDS therapy
@nl
prefLabel
Molecular targets for AIDS therapy
@ast
Molecular targets for AIDS therapy
@en
Molecular targets for AIDS therapy
@nl
P2093
P356
P1433
P1476
Molecular targets for AIDS therapy
@en
P2093
P304
P356
10.1126/SCIENCE.1699273
P407
P577
1990-09-28T00:00:00Z